Amylyx Pharmaceuticals (AMLX) Payables (2021 - 2025)
Historic Payables for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $5.3 million.
- Amylyx Pharmaceuticals' Payables rose 25904.51% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 25904.51%. This contributed to the annual value of $2.9 million for FY2024, which is 8667.78% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Payables stood at $5.3 million for Q3 2025, which was up 25904.51% from $3.3 million recorded in Q2 2025.
- Amylyx Pharmaceuticals' Payables' 5-year high stood at $24.7 million during Q2 2023, with a 5-year trough of $1.5 million in Q3 2024.
- Moreover, its 5-year median value for Payables was $6.3 million (2022), whereas its average is $9.0 million.
- In the last 5 years, Amylyx Pharmaceuticals' Payables tumbled by 8667.78% in 2024 and then skyrocketed by 25904.51% in 2025.
- Amylyx Pharmaceuticals' Payables (Quarter) stood at $4.4 million in 2021, then soared by 43.12% to $6.3 million in 2022, then soared by 252.58% to $22.1 million in 2023, then plummeted by 86.68% to $2.9 million in 2024, then skyrocketed by 81.66% to $5.3 million in 2025.
- Its last three reported values are $5.3 million in Q3 2025, $3.3 million for Q2 2025, and $4.8 million during Q1 2025.